UniSuper Management Pty Ltd Trims Holdings in Illumina, Inc. (NASDAQ:ILMN)

UniSuper Management Pty Ltd lowered its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 21.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 3,000 shares of the life sciences company’s stock after selling 800 shares during the period. UniSuper Management Pty Ltd’s holdings in Illumina were worth $401,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of ILMN. Elo Mutual Pension Insurance Co lifted its stake in shares of Illumina by 10.1% during the 4th quarter. Elo Mutual Pension Insurance Co now owns 15,581 shares of the life sciences company’s stock valued at $2,082,000 after buying an additional 1,431 shares in the last quarter. WINTON GROUP Ltd raised its holdings in Illumina by 169.6% during the fourth quarter. WINTON GROUP Ltd now owns 38,550 shares of the life sciences company’s stock valued at $5,151,000 after acquiring an additional 24,249 shares during the period. Korea Investment CORP boosted its stake in shares of Illumina by 92.9% in the fourth quarter. Korea Investment CORP now owns 70,588 shares of the life sciences company’s stock worth $9,433,000 after acquiring an additional 34,000 shares during the period. Mendel Money Management bought a new position in shares of Illumina in the fourth quarter worth about $402,000. Finally, Murphy & Mullick Capital Management Corp purchased a new stake in shares of Illumina during the fourth quarter worth about $61,000. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ILMN has been the subject of several recent analyst reports. TD Cowen downgraded Illumina from a “buy” rating to a “hold” rating and dropped their price target for the stock from $177.00 to $140.00 in a research note on Friday, February 7th. Stephens reiterated an “overweight” rating and issued a $156.00 price target on shares of Illumina in a research note on Tuesday, March 11th. Royal Bank of Canada dropped their price objective on shares of Illumina from $247.00 to $128.00 and set an “outperform” rating for the company in a report on Wednesday, March 12th. HSBC cut Illumina from a “buy” rating to a “hold” rating and set a $100.00 target price on the stock. in a report on Friday, February 28th. Finally, Citigroup dropped their price target on Illumina from $130.00 to $90.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $140.90.

Illumina Stock Performance

Shares of NASDAQ:ILMN opened at $79.34 on Tuesday. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 12 month low of $77.54 and a 12 month high of $156.66. The company has a market capitalization of $12.57 billion, a price-to-earnings ratio of -10.33, a PEG ratio of 1.60 and a beta of 1.17. The firm’s 50-day moving average is $101.65 and its 200 day moving average is $126.49.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Research analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.